The Schwab U.S. Dividend Equity ETF is a top pick for conservative investors seeking stable returns & dividend growth. Click ...

Combining talazoparib with enzalutamide significantly improves overall survival in patients with metastatic ...

Payouts to shareholders of large publicly traded health companies more than tripled over the past two decades, new research ...

A novel transcatheter-implanted system that shunts blood flow from the left to right atrium through the coronary sinus has ...

AbbVie is a resurging Dividend King. Amgen's recent clinical setback makes its stock available at a discount. Gilead Sciences ...

Amgen (NASDAQ: AMGN) will present at Citi's 2025 Virtual Oncology Leadership Summit at 3:00 p.m. ET on Wednesday, Feb. 19, 2025. Jean-Charles Soria, senior vice president of oncology within global ...

Novo Nordisk announced plans for a longer phase III trial testing its investigational obesity drug CagriSema, with regulatory ...

At recent prices, you can buy shares of Merck (NYSE: MRK) that offer a yield above 3%, and shares of Pfizer (NYSE: PFE) offer ...

Amgen Inc. closed 16.06% short of its 52-week high of $346.85, which the company reached on July 25th.

Gladstone Institutional Advisory LLC trimmed its holdings in Amgen Inc. (NASDAQ:AMGN – Free Report) by 18.9% in the fourth ...

While Ideaya is letting Amgen go, it is retaining an interest in MAT2A-PRMT5 combinations. Ideaya has a PRMT5 inhibitor, ...

Citi analyst Geoff Meacham maintained a Hold rating on Amgen (AMGN – Research Report) today and set a price target of $295.00. The company’s ...